FarooquiKJMithalAKerwenAK, et al. Type 2 diabetes and bone fragility- an under-recognized association. Diabetes Metab Syndr. 2021;15:927-935.
2.
American Diabetes Association. Standards of medical care in diabetes-2022. Diabetes Care. 2022;45(suppl 1):S1-264.
3.
ZhangZCaoYangTaoY, et al. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract. 2020;159:107990. doi:10.1016/j.diabres.2019.107990
4.
TaoYEMShiJ, et al. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study. Aging Clin Exp Res. 2021;33:2133-2139.
5.
NealBPerkovicVMahaffeyKW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
6.
ZhouZJardineMPerkovicV, et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 2019;62:1854-1867.
7.
PerkovicVJardineMJNealB, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306.
8.
DriessenJHvan den BerghJPvan OnzenoortHA, et al. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. Diabetes Obes Metab. 2017;19(3):421-428.
9.
FuJZhuJHaoY, et al. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep. 2016;6:29104. doi:10.1038/srep29104
10.
MonamiMAntenoreADicembriniI, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34:2474-2476
11.
ChengLHuYLiYY, et al. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2019;35:e3168. doi:10.1002/dmrr.3168
12.
ZhangYSWengWYXieBC, et al. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int. 2018;29:2639-2644.
13.
SuBShengHZhangM, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48:107-115.
14.
ZinmanBWannerCLachinJM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
15.
WiviottSDRazIBonacaMP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4):347-357.
16.
CannonCPPratleyRDagogo-JackS, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425-1435.
17.
ZhuoMHawleyCEPaikJM, et al. Association of sodium-glucose cotransporter-2 inhibitors with fracture risk in older adults with type 2 diabetes. JAMA Netw Open. 2021;4(10):e2130762. doi:10.1001/jamanetworkopen.2021.30762
18.
HaKHKimDJChoiYJ. Sodium-glucose co-transporter-2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study. J Diabetes Investig2022;13(6):986-996. doi:10.1111/jdi.13768
19.
TaylorSIBlauJERotherKI. Possible adverse effects of SGLT2 inhibitors on one. Lancet Diabetes Endocrinol. 2015;3:8-10.
